ILAO
Island Pharmaceuticals Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Island Pharmaceuticals Limited - Option Expiring 14-Mar-2025
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.09
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in ILAO
1
π Total Capital Earnings
N/A
π Average investment frequency
3 days
π΅ Average investment amount
$5,000
β° Last time a customer invested in ILAO
25 days
ILAO investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
100%
πΆ Age of investors
18 - 25
26 - 34
100%
35 - 90
π Legal gender of investors
Female
Male
100%
Pearlers who invest in ILAO also invest in...
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6041.2m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
π Performance (5Yr p.a)
4.86%
π Share price
$140.68 AUD
π¦πΊ AUSTRALIA
πΈ FINANCIALS
β³οΈ DIVERSIFIED
PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. The Companyβs segments include Corporate and Research. The firm is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The firm's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The firm is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. The company is focused on starting Phase II/III clinical study of MPL. The company has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. The company is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.
π Performance (5Yr p.a)
15.38%
π Share price
$0.23 AUD
π¦ LOGISTICS
π HIGH PRICE GROWTH
Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.
π Performance (5Yr p.a)
187.14%
π Share price
$1.45 AUD
𧬠BIOTECHNOLOGY
QSML.AX was created on 2021-03-08 by VanEck. The fund's investment portfolio concentrates primarily on small cap equity. The Fund gives investors a diversified portfolio of 150 international developed market small-cap quality growth companies having durable business models and sustainable competitive advantages.
π Share price
$31.27 AUD
π INDUSTRIALS
π GLOBAL
EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 163.18m in AUM and 204 holdings. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index).
π Performance (5Yr p.a)
4.93%
π Share price
$25.00 AUD
π€ TECHNOLOGY
π GLOBAL
Want more shares? Try these...
ILB.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The fund aims to provide investors with the performance of the Bloomberg AusBond Inflation Government 0+ Yr Index, before fees and expenses. The index is designed to measure the performance of a segment of the Australian bond market comprised of inflation-linked fixed income securities.
π Performance (5Yr p.a)
-0.69%
π Share price
$124.35 AUD
ILC.AX was created on 2010-12-06 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 664.02m in AUM and 21 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of the 20 largest Australian securities listed on the ASX.
π Performance (5Yr p.a)
4.81%
π Share price
$32.30 AUD
πΈ FINANCIALS
𧱠MATERIALS
π° HIGH DIVIDEND
IKO.AX was created on 2000-05-09 by iShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide investors with the performance of the MSCI Korea 25/50 Index, before fees and expenses. The index is designed to measure the performance of Korean large-, mid- & small- capitalisation companies
π Performance (5Yr p.a)
0.68%
π Share price
$90.24 AUD
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
KOREA
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The firm operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
π Share price
$0.17 AUD
π¦ LOGISTICS